<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31923281</article-id><article-id pub-id-type="pmc">6953842</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0227139</article-id><article-id pub-id-type="publisher-id">PONE-D-19-18610</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Nosocomial Infections</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial Control</subject><subj-group><subject>Antimicrobial Resistance</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Antimicrobial Resistance</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Economics</subject><subj-group><subject>Economic Analysis</subject><subj-group><subject>Economic Impact Analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Economics</subject><subj-group><subject>Health Economics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Health Care</subject><subj-group><subject>Health Economics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Database and Informatics Methods</subject><subj-group><subject>Database Searching</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Urology</subject><subj-group><subject>Urinary Tract Infections</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Research Assessment</subject><subj-group><subject>Systematic Reviews</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Health Care</subject><subj-group><subject>Health Care Facilities</subject><subj-group><subject>Hospitals</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Impact of multi-drug resistant bacteria on economic and clinical outcomes of healthcare-associated infections in adults: Systematic review and meta-analysis</article-title><alt-title alt-title-type="running-head">Impact of multi-drug resistant bacterial healthcare acquired infections</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-8595-1224</contrib-id><name><surname>Serra-Burriel</surname><given-names>Miquel</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5647-9637</contrib-id><name><surname>Keys</surname><given-names>Matthew</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7553-597X</contrib-id><name><surname>Campillo-Artero</surname><given-names>Carlos</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-4405-8162</contrib-id><name><surname>Agodi</surname><given-names>Antonella</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0905-5003</contrib-id><name><surname>Barchitta</surname><given-names>Martina</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gikas</surname><given-names>Achilleas</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Palos</surname><given-names>Carlos</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>L&#x000f3;pez-Casasnovas</surname><given-names>Guillem</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Center for Research in Health and Economics, Pompeu Fabra University, Barcelona, Spain</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Balearic Islands Health Service, Palma de Mallorca, Balearic Islands, Spain</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Medical and Surgical Sciences and Advanced Technologies &#x0201c;GF Ingrassia&#x0201d;, University of Catania, Catania, Italy</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Internal Medicine Department, Infectious Diseases Unit, University Hospital of Heraklion, Crete, Greece</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>School of Medicine, University of Crete, Heraklion, Greece</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Hospital Beatriz &#x000c2;ngelo, Loures, Lisbon, Portugal</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Cheungpasitporn</surname><given-names>Wisit</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of Mississippi Medical Center, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>I have read the journal's policy and the authors of this manuscript have the following competing interests: MSB acknowledges research grants from Horizon2020, EiTHealth and ISCI programs outside of the submitted work, MK;CCA;AA;MB;CP;GLC declare no competing interests.</p></fn><corresp id="cor001">* E-mail: <email>miquel.serrab@upf.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>15</volume><issue>1</issue><elocation-id>e0227139</elocation-id><history><date date-type="received"><day>1</day><month>7</month><year>2019</year></date><date date-type="accepted"><day>12</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Serra-Burriel et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Serra-Burriel et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0227139.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Infections with multidrug resistant (MDR) bacteria in hospital settings have substantial implications in terms of clinical and economic outcomes. However, due to clinical and methodological heterogeneity, estimates about the attributable economic and clinical effects of healthcare-associated infections (HAI) due to MDR microorganisms (MDR HAI) remain unclear. The objective was to review and synthesize the evidence on the impact of MDR HAI in adults on hospital costs, length of stay, and mortality at discharge.</p></sec><sec id="sec002"><title>Methods and findings</title><p>Literature searches were conducted in PubMed/MEDLINE, and Google Scholar databases to select studies that evaluated the impact of MDR HAI on economic and clinical outcomes. Eligible studies were conducted in adults, in order to ensure homogeneity of populations, used propensity score matched cohorts or included explicit confounding control, and had confirmed antibiotic susceptibility testing. Risk of bias was evaluated, and effects were measured with ratios of means (ROM) for cost and length of stay, and risk ratios (RR) for mortality. A systematic search was performed on 14<sup>th</sup> March 2019, re-run on the 10<sup>th</sup> of June 2019 and extended the 3<sup>rd</sup> of September 2019. Small effect sizes were assessed by examination of funnel plots. Sixteen articles (6,122 patients with MDR HAI and 8,326 patients with non-MDR HAI) were included in the systematic review of which 12 articles assessed cost, 19 articles length of stay, and 14 mortality. Compared to susceptible infections, MDR HAI were associated with increased cost (ROM 1.33, 95%CI [1.15; 1.54]), prolonged length of stay (ROM 1.27, 95%CI [1.18; 1.37]), and excess in-hospital mortality (RR 1.61, 95%CI [1.36; 1.90]) in the random effects models. Risk of publication bias was only found to be significant for mortality, and overall study quality good.</p></sec><sec id="sec003"><title>Conclusions</title><p>MDR HAI appears to be strongly associated with increases in direct cost, prolonged length of stay and increased mortality. However, further comprehensive studies in this setting are warranted.</p></sec><sec id="sec004"><title>Trial registration</title><p>PROSPERO (<ext-link ext-link-type="uri" xlink:href="https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42019126288">CRD42019126288</ext-link>).</p></sec></abstract><funding-group><funding-statement>GLC: unrestricted grant for the study of the consequences of antimicrobial resistance. Angelini SpA.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="1"/><page-count count="14"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>The growing prevalence of bacterial infections that cannot be adequately treated by existing effective antimicrobial therapies poses a considerable threat to the effectiveness, efficiency of healthcare systems[<xref rid="pone.0227139.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="pone.0227139.ref006" ref-type="bibr">6</xref>], and is currently reaching societal consequences[<xref rid="pone.0227139.ref007" ref-type="bibr">7</xref>&#x02013;<xref rid="pone.0227139.ref009" ref-type="bibr">9</xref>] limiting the achievement of WHO&#x02019;s Sustainable Development Goals[<xref rid="pone.0227139.ref010" ref-type="bibr">10</xref>,<xref rid="pone.0227139.ref011" ref-type="bibr">11</xref>].</p><p>Much work has been done on understanding and estimating the impact of antimicrobial resistance (AMR) in various settings. A recent article[<xref rid="pone.0227139.ref012" ref-type="bibr">12</xref>] underlines that AMR is one of the greatest challenges for public health and highlights the high impact of healthcare-associated infections (HAIs) due to antimicrobial resistant bacteria in terms of number of cases, attributable deaths, and disability-adjusted life-years. 700.000 deaths due to infections caused by Multi-drug resistant (MDR) bacteria occur yearly worldwide and this number could increase to 10 million in 2050[<xref rid="pone.0227139.ref013" ref-type="bibr">13</xref>] depending upon resistance patterns evolution and effective antibiotic discovery. Estimated associated costs are estimated to be 3.8% of annual GDP (additional 1.2 trillion USD) and as a results, 28.3 million people are condemned to extreme poverty. &#x0201c;<italic>Three out of four deaths from superbug infections could be averted by spending just USD 2 per person a year on measures as simple as hand washing and more prudent prescription of antibiotics</italic>&#x0201d;[<xref rid="pone.0227139.ref014" ref-type="bibr">14</xref>].</p><p>With respect to AMR, the most commonly reported characterization is multidrug resistance (MDR)[<xref rid="pone.0227139.ref015" ref-type="bibr">15</xref>&#x02013;<xref rid="pone.0227139.ref019" ref-type="bibr">19</xref>], which occurs when a bacterial infection is resistant to treatment with multiple appropriate antimicrobial drugs. MDR is currently characterized as non-susceptibility to at least one agent in three antimicrobial categories [<xref rid="pone.0227139.ref020" ref-type="bibr">20</xref>]. Associations between resistant infections and a wide arrange of outcomes has been reported and their direct effects are mainly driven by the ineffectiveness of available treatment of such infections. However, the relative magnitude of effects remains unclear. Moreover, estimates of the iatrogenic burden of MDR in hospital nosocomial infections could have been biased due to small sample sizes studies, inadequate research methodology and measurement error.</p><p>The objective of this study was to systematically review the literature and to provide a quantitative synthesis of the available evidence regarding the adjusted association between HAI due to MDR bacteria and direct cost of care, extended length of stay and mortality in observational studies with the highest degree of internal validity.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Materials and methods</title><p>This systematic review and meta-analysis adheres to the PRISMA recommendations[<xref rid="pone.0227139.ref021" ref-type="bibr">21</xref>]. Furthermore, specific recommendations for systematic review and metanalysis of observational studies were followed[<xref rid="pone.0227139.ref022" ref-type="bibr">22</xref>]. This metanalysis was registered with PROSPERO (CRD42019126288).</p><sec id="sec007"><title>Study eligibility criteria</title><p>Studies met eligibility criteria if they were case-control or cohort studies conducted in adults evaluating the effects of MDR HAI vs non-MDR HAI. We excluded non-adjusted studies due to the excess risk of bias within the observational setting of this analysis. Two consecutive rounds of eligibility criteria were applied to ensure comparability across studies.</p><p>First, each included study must: i) have been published between 1st January 1980 - 3rd September 2019 in English, ii) attempt to estimate the direct impact of MDR (MDR was defined in accordance to the current available interim expert proposal[<xref rid="pone.0227139.ref020" ref-type="bibr">20</xref>]) HAIs on either clinical or economic outcomes using original data with a case-control or cohort study design, and, iii) attempt to control for confounding either through matching[<xref rid="pone.0227139.ref023" ref-type="bibr">23</xref>], inclusion of sensible covariates in a multivariate analysis, or both[<xref rid="pone.0227139.ref024" ref-type="bibr">24</xref>].</p><p>A second round of eligibility criteria was applied upon examination of the full text of each study for inclusion in the systematic review. In particular, each study must: i) have a control group that differs in the antibiotic susceptibility pattern of the microorganism causing infections (confirmed by susceptibility testing), ii) present comprehensive descriptive statistics (gender composition, age, microorganism distribution) of the case and control groups with estimated variance parameters of the dependent variables, iii) examine at least one of the following outcomes: mortality at discharge, direct hospital cost/charges or length of stay, and, iv) in case of inclusion of community-acquired infection (CAI) cases, results had to be reported separately for CAI and HAI cases while fulfilling the previous inclusion conditions.</p></sec><sec id="sec008"><title>Identification and selection of studies</title><p>A systematic search was performed on 14<sup>th</sup> March 2019,re-run on the 10<sup>th</sup> of June 2019 and extended the 3<sup>rd</sup> of September 2019. We searched PubMed/MEDLINE and Google Scholar databases for eligible studies. Two authors (MSB and MK) performed the title screening to find retrospective or prospective studies reporting an adjusted association of MDR HAI with mortality, length of stay and/or direct cost of care. A specific-search strategy was tailored to each database by using MeSH/Map terms and is presented as supplementary <xref ref-type="supplementary-material" rid="pone.0227139.s007">S3 Table</xref>. The degree of agreement across the two reviewers for inclusion assessment was assessed using kappa statistics.</p><p>Additional papers were also collected through expert consultation, and references of individual papers and previous meta-analyses. The search flow chart is presented in <xref ref-type="fig" rid="pone.0227139.g001">Fig 1</xref>.</p><fig id="pone.0227139.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227139.g001</object-id><label>Fig 1</label><caption><title>PRISMA flow diagram.</title></caption><graphic xlink:href="pone.0227139.g001"/></fig></sec><sec id="sec009"><title>Data extraction and risk of bias assessment</title><p>Two predefined tables were used to summarize information from the final eligible studies. In the first one, for each paper, we recorded the basic results about the estimated impact of MDR HAI on each clinical and economic outcome (adjusted difference, outcomes mean, and, sample sizes). In the second one, we recorded the descriptive statistics provided on the study samples used for the final analysis. Specific Items were extracted for each study: clinical setting, study design (prospective or retrospective), origin of infection (hospital and/or community), infection type. These data extraction procedures were performed by two authors, and disagreement was resolved by discussion with a third author (CC). Three primary outcomes were evaluated: i) direct hospitalization cost or hospital charges, ii) length of stay, and iii) mortality at discharge.</p><p>Direct hospitalization cost was defined as the total direct cost from the hospital perspective of the inpatient admission, when unavailable, hospital charges were used as a proxy. Length of stay was defined as the admission length of stay following infection up to discharge. Mortality was defined as patient death at the time of discharge.</p><p>Various methodologies are regularly employed to control for confounding and to approximate unbiased, causal estimates. In order to assess the risk of bias per study we used the Newcastle-Ottawa Scale designed for assessing the quality of non-randomized studies in a meta-analysis[<xref rid="pone.0227139.ref025" ref-type="bibr">25</xref>&#x02013;<xref rid="pone.0227139.ref027" ref-type="bibr">27</xref>]. Publication bias was assessed with funnel plots.</p></sec><sec id="sec010"><title>Data synthesis</title><p>All statistical analyses were performed in R, version 3.5.1 (2018-07-02)[<xref rid="pone.0227139.ref028" ref-type="bibr">28</xref>] with the meta package[<xref rid="pone.0227139.ref029" ref-type="bibr">29</xref>]. Difference in outcomes was expressed as ratio of means (ROM) for cost and length of stay outcomes, and risk ratio (RR) for mortality at discharge. The rationale for expressing outcomes as ROM, was to eliminate between-studies variability between the reporting of direct hospital cost or charges, both random-effects (RE) and fixed-effects (FE) models were fitted for statistical pooling of the data. Given the clinical heterogeneity present in the analysis, a random effects model with the Hartung-Knapp-Sidik-Jonkman method was chosen as the primary estimation method[<xref rid="pone.0227139.ref030" ref-type="bibr">30</xref>]. The weighting of the results was performed in relation to the sample size of each study. Given the low likelihood of obtaining 10 or more studies by covariate, meta-regression was not performed[<xref rid="pone.0227139.ref031" ref-type="bibr">31</xref>].</p><p>Statistical heterogeneity for each pooled outcome was examined with the I<sup>2</sup> statistic[<xref rid="pone.0227139.ref032" ref-type="bibr">32</xref>] and Q-test[<xref rid="pone.0227139.ref033" ref-type="bibr">33</xref>]. Significance level was established at the 5% level, and all results are expressed with 95% confidence intervals (CI). Prediction interval was also estimated in the pooling[<xref rid="pone.0227139.ref034" ref-type="bibr">34</xref>]. Risk of publication bias was visually examined through funnel plots and assessed with a linear regression test of funnel plot asymmetry[<xref rid="pone.0227139.ref035" ref-type="bibr">35</xref>].</p></sec></sec><sec sec-type="results" id="sec011"><title>Results</title><p><xref ref-type="fig" rid="pone.0227139.g001">Fig 1</xref> depicts a flow diagram of the search, following PRISMA guidelines, screening and eligibility procedures and the loss of studies that occurred throughout. <xref rid="pone.0227139.t001" ref-type="table">Table 1</xref> describes the studies that were included after the second round of eligibility criteria applied to the full-text studies. Out of 733 selected studies, 658 (93.5%) were excluded after screening of the abstract for the first round of inclusion criteria (kappa = 0.73). A total of 48 full-text manuscripts were assessed for the second round of inclusion criteria, with 28 (58.3%) being excluded for not fulfilling the criteria (kappa = 0.96). A total of 20 studies were included in the review, with 14,448 patients included[<xref rid="pone.0227139.ref036" ref-type="bibr">36</xref>&#x02013;<xref rid="pone.0227139.ref055" ref-type="bibr">55</xref>]. Out of the 20 studies, 19 presented in hospital length of stay, 14 presented mortality data and 12 cost outcomes.</p><table-wrap id="pone.0227139.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227139.t001</object-id><label>Table 1</label><caption><title>Summary characteristics of selected studies.</title></caption><alternatives><graphic id="pone.0227139.t001g" xlink:href="pone.0227139.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" style="border-bottom:thick" rowspan="1" colspan="1">Study ID</th><th align="left" style="border-bottom:thick" rowspan="1" colspan="1">Authors</th><th align="center" style="border-bottom:thick" rowspan="1" colspan="1">Year</th><th align="center" style="border-bottom:thick" rowspan="1" colspan="1">Clinical Setting</th><th align="center" style="border-bottom:thick" rowspan="1" colspan="1">Study Design</th><th align="center" style="border-bottom:thick" rowspan="1" colspan="1">Origin of Infection</th><th align="center" style="border-bottom:thick" rowspan="1" colspan="1">Infection Types</th><th align="center" style="border-bottom:thick" rowspan="1" colspan="1">Country of study</th><th align="center" style="border-bottom:thick" rowspan="1" colspan="1">Mean Age</th><th align="center" style="border-bottom:thick" rowspan="1" colspan="1">Sample size (<italic>N</italic>)</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">R. K. Pelz et al.</td><td align="center" rowspan="1" colspan="1">2002</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">Prospective</td><td align="center" rowspan="1" colspan="1">H</td><td align="center" rowspan="1" colspan="1">Any</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" rowspan="1" colspan="1">56</td><td align="center" rowspan="1" colspan="1">34</td></tr><tr><td align="center" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">L. F. Barat et al.</td><td align="center" rowspan="1" colspan="1">2017</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">Prospective</td><td align="center" rowspan="1" colspan="1">ICU</td><td align="center" rowspan="1" colspan="1">PN</td><td align="center" rowspan="1" colspan="1">Spain</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">64</td></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">B. J. Kopp et al.</td><td align="center" rowspan="1" colspan="1">2004</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">Retrospective</td><td align="center" rowspan="1" colspan="1">H/C</td><td align="center" rowspan="1" colspan="1">Any</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">72</td></tr><tr><td align="center" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">R. Tedja et al.</td><td align="center" rowspan="1" colspan="1">2014</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">Retrospective</td><td align="center" rowspan="1" colspan="1">H</td><td align="center" rowspan="1" colspan="1">PN</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" rowspan="1" colspan="1">62</td><td align="center" rowspan="1" colspan="1">107</td></tr><tr><td align="center" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">P. O. Depuydt</td><td align="center" rowspan="1" colspan="1">2008</td><td align="center" rowspan="1" colspan="1">Multicenter</td><td align="center" rowspan="1" colspan="1">Retrospective</td><td align="center" rowspan="1" colspan="1">H/C</td><td align="center" rowspan="1" colspan="1">Any</td><td align="center" rowspan="1" colspan="1">Belgium</td><td align="center" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">192</td></tr><tr><td align="center" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">I. M. Loeches et al.</td><td align="center" rowspan="1" colspan="1">2014</td><td align="center" rowspan="1" colspan="1">Multicenter</td><td align="center" rowspan="1" colspan="1">Prospective</td><td align="center" rowspan="1" colspan="1">ICU</td><td align="center" rowspan="1" colspan="1">PN</td><td align="center" rowspan="1" colspan="1">Spain</td><td align="center" rowspan="1" colspan="1">62</td><td align="center" rowspan="1" colspan="1">171</td></tr><tr><td align="center" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">P. D. Mauldin et al.</td><td align="center" rowspan="1" colspan="1">2010</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">Retrospective</td><td align="center" rowspan="1" colspan="1">H</td><td align="center" rowspan="1" colspan="1">Any</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" rowspan="1" colspan="1">N/A<xref ref-type="table-fn" rid="t001fn002">*</xref></td><td align="center" rowspan="1" colspan="1">662</td></tr><tr><td align="center" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">J. J. Engemann et al.</td><td align="center" rowspan="1" colspan="1">2003</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">Prospective</td><td align="center" rowspan="1" colspan="1">H</td><td align="center" rowspan="1" colspan="1">SSI</td><td align="center" rowspan="1" colspan="1">US<xref ref-type="table-fn" rid="t001fn003"><sup>&#x02126;</sup></xref></td><td align="center" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">286</td></tr><tr><td align="center" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">E. E. Magira et al.</td><td align="center" rowspan="1" colspan="1">2017</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">Retrospective</td><td align="center" rowspan="1" colspan="1">ICU</td><td align="center" rowspan="1" colspan="1">Any</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">300</td></tr><tr><td align="center" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">Y. Carmeli et al.</td><td align="center" rowspan="1" colspan="1">1999</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">Retrospective</td><td align="center" rowspan="1" colspan="1">H/C</td><td align="center" rowspan="1" colspan="1">Any</td><td align="center" rowspan="1" colspan="1">US<xref ref-type="table-fn" rid="t001fn003"><sup>&#x02126;</sup></xref></td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">489</td></tr><tr><td align="center" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">M. Riu et al.</td><td align="center" rowspan="1" colspan="1">2016</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">Retrospective</td><td align="center" rowspan="1" colspan="1">H</td><td align="center" rowspan="1" colspan="1">BSI</td><td align="center" rowspan="1" colspan="1">Spain</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">575</td></tr><tr><td align="center" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">R. R. Roberts et al.</td><td align="center" rowspan="1" colspan="1">2009</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">Retrospective</td><td align="center" rowspan="1" colspan="1">H/C</td><td align="center" rowspan="1" colspan="1">Any</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">338</td></tr><tr><td align="center" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">S.T. Micek et al.</td><td align="center" rowspan="1" colspan="1">2015</td><td align="center" rowspan="1" colspan="1">Multicenter</td><td align="center" rowspan="1" colspan="1">Retrospective</td><td align="center" rowspan="1" colspan="1">H</td><td align="center" rowspan="1" colspan="1">PN</td><td align="center" rowspan="1" colspan="1">EU</td><td align="center" rowspan="1" colspan="1">56</td><td align="center" rowspan="1" colspan="1">740</td></tr><tr><td align="center" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">Z. Chen et al.</td><td align="center" rowspan="1" colspan="1">2018</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">Retrospective</td><td align="center" rowspan="1" colspan="1">H</td><td align="center" rowspan="1" colspan="1">PN</td><td align="center" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">540</td></tr><tr><td align="center" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">A. Resch et al.</td><td align="center" rowspan="1" colspan="1">2009</td><td align="center" rowspan="1" colspan="1">Multicenter</td><td align="center" rowspan="1" colspan="1">Retrospective</td><td align="center" rowspan="1" colspan="1">H/C</td><td align="center" rowspan="1" colspan="1">Any (MRSA)</td><td align="center" rowspan="1" colspan="1">Germany</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">2,052</td></tr><tr><td align="center" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">M. J. Neidell et al.</td><td align="center" rowspan="1" colspan="1">2012</td><td align="center" rowspan="1" colspan="1">Multicenter</td><td align="center" rowspan="1" colspan="1">Retrospective</td><td align="center" rowspan="1" colspan="1">H/C</td><td align="center" rowspan="1" colspan="1">BSI, UTI, PN</td><td align="center" rowspan="1" colspan="1">US<xref ref-type="table-fn" rid="t001fn003"><sup>&#x02126;</sup></xref></td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">1,775</td></tr><tr><td align="center" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">L. Puchter et al.</td><td align="center" rowspan="1" colspan="1">2018</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">Retrospective</td><td align="center" rowspan="1" colspan="1">H/ICU</td><td align="center" rowspan="1" colspan="1">Any</td><td align="center" rowspan="1" colspan="1">Germany</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">84</td></tr><tr><td align="center" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">R. Nelson et al.</td><td align="center" rowspan="1" colspan="1">2018</td><td align="center" rowspan="1" colspan="1">Multicenter</td><td align="center" rowspan="1" colspan="1">Retrospective</td><td align="center" rowspan="1" colspan="1">H</td><td align="center" rowspan="1" colspan="1">Any</td><td align="center" rowspan="1" colspan="1">US VA</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">405</td></tr><tr><td align="center" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">E. Cowie et al.</td><td align="center" rowspan="1" colspan="1">2005</td><td align="center" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">Retrospective</td><td align="center" rowspan="1" colspan="1">H</td><td align="center" rowspan="1" colspan="1">SSI</td><td align="center" rowspan="1" colspan="1">Canada</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">37</td></tr><tr><td align="center" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">Bonnet et al.</td><td align="center" rowspan="1" colspan="1">2019</td><td align="center" rowspan="1" colspan="1">Multicenter</td><td align="center" rowspan="1" colspan="1">Retrospective</td><td align="center" rowspan="1" colspan="1">ICU</td><td align="center" rowspan="1" colspan="1">Any</td><td align="center" rowspan="1" colspan="1">France</td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">5,525</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Abbreviations: H: Hospital, C: community, ICU: Intensive Care Unit, SSI: Surgical Site Infection, BSI: Bloodstream Infection, MRSA: Methicillin-Resistant Staphylococcus Aureus, UTI: Urinary Tract Infection, PN: Pneumonia.</p></fn><fn id="t001fn002"><p>*Study presents discretized age.</p></fn><fn id="t001fn003"><p><sup>&#x02126;</sup>Hospital charges instead of cost reported.</p></fn></table-wrap-foot></table-wrap><p>Most studies were single center (k = 13). Four studies were prospective cohort studies, while the rest (k = 16) were retrospective. Only four studies were conducted in the intensive care units (ICU), while the remaining studies were conducted in other wards, with some including both community-acquired infections and HAI reported separately (k = 6). In terms of type of infection, most studies included any HAI (k = 11), while the rest, pneumonia (k = 6), bloodstream infections (BSI, k = 2), surgical site infections (SSI, k = 2), and urinary tract infections (UTI, k = 1).</p><sec id="sec012"><title>Risk of bias</title><p>Risk of bias was rated according to the Newcastle-Ottawa scale and is summarized in <xref ref-type="supplementary-material" rid="pone.0227139.s005">S1 Table</xref>. The majority of studies were rated as good quality according to the AHQR[<xref rid="pone.0227139.ref026" ref-type="bibr">26</xref>], (k = 9). Six studies were classified as fair and five of poor quality. Case definition was adequately portrayed in most studies (k = 14), selection of controls (k = 17), definition of controls (k = 12), and representativeness of the sample (k = 11). Comparability of cases and controls on the was rated at least with one point (*) in all studies (k = 20). Ascertainment of exposure was adequate in almost all studies (k = 18). Overall, the risk of bias in included studies was found to be low.</p></sec><sec id="sec013"><title>Effects of MDR-HAI</title><sec id="sec014"><title>Cost</title><p>Excess attributable cost of MDR HAI was found to be statistically significant in the RE pooling (ROM 1.33 95%CI [1.15; 1.54]). <xref ref-type="fig" rid="pone.0227139.g002">Fig 2</xref> presents the results of the pooling. FE pooling displayed similar results (ROM 1.35 95%CI [1.26; 1.44]), and the prediction interval ranged from 0.81 to 2.20. Significant heterogeneity across studies was found to be present with a Q-statistic value of 44.09 (p&#x0003c;0.01) and an I<sup>2</sup> statistic of 75%. There was no evidence of publication bias in the 11 studies that reported cost outcomes with the linear regression test of funnel plot asymmetry (p = 0.7715).</p><fig id="pone.0227139.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227139.g002</object-id><label>Fig 2</label><caption><title>Cost of care ratio of means (ROM) estimates.</title></caption><graphic xlink:href="pone.0227139.g002"/></fig></sec><sec id="sec015"><title>Length of stay</title><p>Prolonged length of stay of MDR HAI was found to be also significant in the RE pooling (ROM 1.27 95%CI [1.17; 1.39]). FE model yielded similar results (ROM 1.21 [1.17; 1.24]). The prediction interval was found to be narrower than for cost with values ranging from 0.97 to 1.65. <xref ref-type="fig" rid="pone.0227139.g003">Fig 3</xref> presents the results. Heterogeneity was also found to be present, Q-statistic value of 59.38 (p&#x0003c;0.01) and I<sup>2</sup> value of 69%. We were not able to reject the null hypothesis of symmetry in the funnel plot (p = 0.1258).</p><fig id="pone.0227139.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227139.g003</object-id><label>Fig 3</label><caption><title>Length of stay ratio of means (ROM) estimates.</title></caption><graphic xlink:href="pone.0227139.g003"/></fig></sec><sec id="sec016"><title>Mortality at discharge</title><p>Excess mortality results from the 14 eligible studies are displayed in <xref ref-type="fig" rid="pone.0227139.g004">Fig 4</xref>. RE pooling shows a significant increase (RR 1.61 95%CI [1.36; 1.90]). FE pooled estimates were much lower than RE (RR 1.27 95%CI [1.21; 1.33]), while the prediction interval ranges from 0.94 to 2.74. Significant heterogeneity across studies was found, Q-statistic 48.49 (p&#x0003c;0.01) and I<sup>2</sup> statistic of 73%.</p><fig id="pone.0227139.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227139.g004</object-id><label>Fig 4</label><caption><title>Mortality at discharge relative risk estimates.</title></caption><graphic xlink:href="pone.0227139.g004"/></fig><p><xref ref-type="fig" rid="pone.0227139.g005">Fig 5</xref> displays the funnel plots of all three outcomes. Symmetry was confirmed for cost and length of stay outcomes, while for mortality a significant asymmetry towards increased RR was noted (p&#x0003c;0.01), highlighting a high risk of publication bias in this particular outcome.</p><fig id="pone.0227139.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227139.g005</object-id><label>Fig 5</label><caption><title>Funnel plots.</title></caption><graphic xlink:href="pone.0227139.g005"/></fig></sec></sec></sec><sec sec-type="conclusions" id="sec017"><title>Discussion</title><p>HAIs can occur in almost every step of hospital care and are highly heterogeneous in their cause and clinical presentation. It follows that a prominent feature of the literature on the economic and clinical impact of MDR is a large degree of heterogeneity across study settings. Here we reviewed and synthesized the available evidence presented with the highest observational methodological standards due to well understood confounding problems[<xref rid="pone.0227139.ref056" ref-type="bibr">56</xref>]. We limited the analysis to cohort and case-control studies in order to alleviate selection bias, excluding a significant portion of studies, and yielding a small number of studies. Overall, the quality of studies was good, we did, however, found indication of publication bias in mortality estimates.</p><p>We found consistent patterns that indicate increased mortality and resource utilization in terms of length of stay and direct cost which are associated with MDR HAI vs those associated with susceptible microorganism acquired infections. We report 1.27, 1.33 and 1.62-fold increases in excess length of stay, cost and mortality at discharge risk associated with MDR respectively. The effect size of length and cost does not vary significantly depending upon the estimation method. However, for mortality, there is a two-fold difference between RE (RR 1.62) and FE (RR 1.27). This difference highlights the potential unobserved heterogeneity across studies in terms of patient prognosis and publication bias. The interrelation of these three outcomes plays a crucial role in the interpretation of the results. Higher inpatient mortality could, theoretically, even reduce inpatient stay and direct hospital cost. However, our estimates point to an overall increase around 30% for resource utilization.</p><p>As is the case with observational studies where the exposure is not randomized, there is risk of bias in estimating the impact of exposure. Only 4 out of 20 eligible studies presented a prospective cohort study design that could mitigate selection bias in the estimates. Remaining studies presented retrospective designs and attempted to overcome other sources of bias through a process matching and/or multivariate modelling with appropriate selection of control variables.</p><p>The range of costs presented varies considerably according to the setting in which MDR HAIs were studied, ranging from average increases of 3,000 USD to 40,000 USD[<xref rid="pone.0227139.ref036" ref-type="bibr">36</xref>,<xref rid="pone.0227139.ref037" ref-type="bibr">37</xref>]. The reported mechanisms of cost impact also vary across settings. We tried to address this between-studies heterogeneity by using a ROM metric as outcome, rendering interpretable estimates regardless of institutional and national setting[<xref rid="pone.0227139.ref057" ref-type="bibr">57</xref>]. The most consistent mechanism across studies refers to secondary antibiotic treatment, followed by prolonged length of stay and increased labor costs. Furthermore, the MDR cost impact has an average incremental estimate of a 1.33-fold magnitude, highlighting the relative magnitude of the problem.</p><p>Further well-designed studies, that use either a consistent control, matching or time-to-infection control, like Nelson et al. (2018) are needed in order to best approximate unbiased and consistent estimates. Their clinical and economic implications are crucial for both the development of novel antibiotics alongside their potential cost-effectiveness estimates.</p><sec id="sec018"><title>Limitations</title><p>There are several limitations to this systematic review. There is a general lack of comparability across studies examining the impact of MDR HAI on clinical and economic outcomes, namely in setting, MDR bacteria and infections studied, data presentation, and methodology. Given the potential lack of exogenous variation in the allocation of resistant bacterial infections, confounding may be a problem, which would require elaborate and uniform covariate choice across participating studies so that a comprehensive set of covariates could be used in a multivariate pooled analysis. No restrictions regarding time to HAI were applied for its definition. However, most studies used a 48H window since admission.</p><p>Furthermore, there are subtle differences in the definitions of primary endpoints utilized across the eligible studies and MDR definitions, which makes comparison less reliable. For example, one may formulate cost from either the patient or hospital perspective, which may be an estimate of cost rather than the true figure, which poses measurement error. Lastly, a complex grouping of studies was chosen for this meta-analysis. We considered all bacteria types presenting with resistant and many types of infections. Comparisons between these different settings are made more difficult by the inconsistencies across studies. We were also unable to perform reliable subgroup analyses due to the small sample size of eligible studies in each predefined category.</p><p>Finally, our search strategy did not include studies published in non-English languages, potentially yielding under representation of geographic areas where AMR presents an even higher burden. <xref ref-type="fig" rid="pone.0227139.g006">Fig 6</xref> presents the geographical distribution of included studies, mainly in North America and Europe. Further research estimating the pooled burden in non-English speaking countries is warranted in order to provide accurate estimates of the magnitude of the burden.</p><fig id="pone.0227139.g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227139.g006</object-id><label>Fig 6</label><caption><title>Geographical distribution of included studies.</title></caption><graphic xlink:href="pone.0227139.g006"/></fig></sec><sec id="sec019"><title>Conclusions</title><p>MDR HAI appears to be strongly associated with increased resource utilization and health outcomes, as assessed by direct provider cost and/or charges, prolonged length of stay and mortality of patients in a wide array of healthcare settings. However, more research is required to fully elucidate the relationship between MDR and economic and clinical outcomes and its dependence on various settings, routes of infection and pathogens involved. Further applied research should focus on the development of prospective registries with standardized susceptibility testing and longer follow-up outside of hospital settings to better understand the actual societal burden of such a rising phenomenon.</p></sec></sec><sec sec-type="supplementary-material" id="sec020"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0227139.s001"><label>S1 Checklist</label><caption><title>PRISMA checklist.</title><p>(DOC)</p></caption><media xlink:href="pone.0227139.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0227139.s002"><label>S1 Code</label><caption><p>(R)</p></caption><media xlink:href="pone.0227139.s002.r"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0227139.s003"><label>S1 Data</label><caption><p>(XLSX)</p></caption><media xlink:href="pone.0227139.s003.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0227139.s004"><label>S1 Results</label><caption><p>(DOCX)</p></caption><media xlink:href="pone.0227139.s004.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0227139.s005"><label>S1 Table</label><caption><title>Summary of Newcastle-Ottawa risk of bias judgements for each study.</title><p>(DOCX)</p></caption><media xlink:href="pone.0227139.s005.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0227139.s006"><label>S2 Table</label><caption><title>Quantitative summary of included studies.</title><p>(DOCX)</p></caption><media xlink:href="pone.0227139.s006.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0227139.s007"><label>S3 Table</label><caption><title>Search strategy by database.</title><p>(DOCX)</p></caption><media xlink:href="pone.0227139.s007.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>MDR</term><def><p>multidrug resistance</p></def></def-item><def-item><term>HAI</term><def><p>hospital acquired infection</p></def></def-item><def-item><term>ICU</term><def><p>intensive care unit</p></def></def-item><def-item><term>ECDC</term><def><p>European Center for Disease Prevention and Control</p></def></def-item><def-item><term>CAI</term><def><p>community acquired infection</p></def></def-item><def-item><term>HAI</term><def><p>healthcare acquired infection</p></def></def-item><def-item><term>SSI</term><def><p>surgical site infections</p></def></def-item><def-item><term>CL-BSI</term><def><p>central line bloodstream infections</p></def></def-item><def-item><term>CAUTIs</term><def><p>catheter associated urinary tract infection</p></def></def-item><def-item><term>VAP</term><def><p>ventilator associated pneumonia</p></def></def-item><def-item><term>WHO</term><def><p>World Health Organization</p></def></def-item><def-item><term>XDR</term><def><p>extensively drug resistance</p></def></def-item><def-item><term>PDR</term><def><p>pan drug resistance</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="pone.0227139.ref001"><label>1</label><mixed-citation publication-type="other">Stygall J, Newman S. Hospital acquired infection. Cambridge Handbook of Psychology, Health and Medicine, Second Edition. 2014. <pub-id pub-id-type="doi">10.1017/CBO9780511543579.182</pub-id></mixed-citation></ref><ref id="pone.0227139.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Eliopoulos</surname><given-names>GM</given-names></name>, <name><surname>Cosgrove</surname><given-names>SE</given-names></name>, <name><surname>Carmeli</surname><given-names>Y</given-names></name>. <article-title>The Impact of Antimicrobial Resistance on Health and Economic Outcomes</article-title>. <source>Clin Infect Dis</source>. <year>2003</year>; <pub-id pub-id-type="doi">10.1086/375081</pub-id>
<pub-id pub-id-type="pmid">12766839</pub-id></mixed-citation></ref><ref id="pone.0227139.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Friedman</surname><given-names>ND</given-names></name>, <name><surname>Temkin</surname><given-names>E</given-names></name>, <name><surname>Carmeli</surname><given-names>Y</given-names></name>. <article-title>The negative impact of antibiotic resistance</article-title>. <source>Clinical Microbiology and Infection</source>. <year>2016</year>
<pub-id pub-id-type="doi">10.1016/j.cmi.2015.12.002</pub-id>
<pub-id pub-id-type="pmid">26706614</pub-id></mixed-citation></ref><ref id="pone.0227139.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Hidron</surname><given-names>AI</given-names></name>, <name><surname>Edwards</surname><given-names>JR</given-names></name>, <name><surname>Patel</surname><given-names>J</given-names></name>, <name><surname>Horan</surname><given-names>TC</given-names></name>, <name><surname>Sievert</surname><given-names>DM</given-names></name>, <name><surname>Pollock</surname><given-names>DA</given-names></name>, <etal>et al</etal>
<article-title>Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006&#x02013;2007</article-title>. <source>Infect Control Hosp Epidemiol</source>. <year>2008</year>; <pub-id pub-id-type="doi">10.1086/591861</pub-id>
<pub-id pub-id-type="pmid">18947320</pub-id></mixed-citation></ref><ref id="pone.0227139.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Livermore</surname><given-names>DM</given-names></name>. <article-title>Bacterial Resistance: Origins, Epidemiology, and Impact</article-title>. <source>Clin Infect Dis</source>. <year>2003</year>; <pub-id pub-id-type="doi">10.1086/344654</pub-id>
<pub-id pub-id-type="pmid">12516026</pub-id></mixed-citation></ref><ref id="pone.0227139.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Nathwani</surname><given-names>D</given-names></name>, <name><surname>Raman</surname><given-names>G</given-names></name>, <name><surname>Sulham</surname><given-names>K</given-names></name>, <name><surname>Gavaghan</surname><given-names>M</given-names></name>, <name><surname>Menon</surname><given-names>V</given-names></name>. <article-title>Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: A systematic review and meta-analysis</article-title>. <source>Antimicrob Resist Infect Control</source>. <year>2014</year>; <pub-id pub-id-type="doi">10.1186/2047-2994-3-32</pub-id>
<pub-id pub-id-type="pmid">25371812</pub-id></mixed-citation></ref><ref id="pone.0227139.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Roberts</surname><given-names>RR</given-names></name>, <name><surname>Hota</surname><given-names>B</given-names></name>, <name><surname>Ahmad</surname><given-names>I</given-names></name>, <name><surname>Scott</surname><given-names>R</given-names></name>. <name><surname>Douglas</surname><given-names>II</given-names></name>, <name><surname>Foster</surname><given-names>SD</given-names></name>, <name><surname>Abbasi</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Hospital and Societal Costs of Antimicrobial-Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic Stewardship</article-title>. <source>Clin Infect Dis</source>. <year>2009</year>;<volume>49</volume>: <fpage>1175</fpage>&#x02013;<lpage>1184</lpage>. Available: <pub-id pub-id-type="doi">10.1086/605630</pub-id>
<pub-id pub-id-type="pmid">19739972</pub-id></mixed-citation></ref><ref id="pone.0227139.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Kirkland</surname><given-names>KB</given-names></name>, <name><surname>Briggs</surname><given-names>JP</given-names></name>, <name><surname>Trivette</surname><given-names>SL</given-names></name>, <name><surname>Wilkinson</surname><given-names>WE</given-names></name>, <name><surname>Sexton</surname><given-names>DJ</given-names></name>. <article-title>The Impact of Surgical-Site Infections in the 1990s: Attributable Mortality, Excess Length of Hospitalization, And Extra Costs</article-title>. <source>Infect Control &#x00026; Hosp Epidemiol</source>. 2015/01/02. Cambridge University Press; <year>1999</year>;<volume>20</volume>: <fpage>725</fpage>&#x02013;<lpage>730</lpage>. <pub-id pub-id-type="doi">10.1086/501572</pub-id>
<pub-id pub-id-type="pmid">10580621</pub-id></mixed-citation></ref><ref id="pone.0227139.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Stone</surname><given-names>PW</given-names></name>. <article-title>Economic burden of healthcare-associated infections: an American perspective</article-title>. <source>Expert Rev Pharmacoecon Outcomes Res</source>. Taylor &#x00026; Francis; <year>2009</year>;<volume>9</volume>: <fpage>417</fpage>&#x02013;<lpage>422</lpage>. <pub-id pub-id-type="doi">10.1586/erp.09.53</pub-id>
<pub-id pub-id-type="pmid">19817525</pub-id></mixed-citation></ref><ref id="pone.0227139.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Jasovsk&#x000fd;</surname><given-names>D</given-names></name>, <name><surname>Littmann</surname><given-names>J</given-names></name>, <name><surname>Zorzet</surname><given-names>A</given-names></name>, <name><surname>Cars</surname><given-names>O</given-names></name>. <article-title>Antimicrobial resistance-a threat to the world&#x02019;s sustainable development</article-title>. <source>Ups J Med Sci</source>. 2016/07/13. Taylor &#x00026; Francis; <year>2016</year>;<volume>121</volume>: <fpage>159</fpage>&#x02013;<lpage>164</lpage>. <pub-id pub-id-type="doi">10.1080/03009734.2016.1195900</pub-id>
<pub-id pub-id-type="pmid">27416324</pub-id></mixed-citation></ref><ref id="pone.0227139.ref011"><label>11</label><mixed-citation publication-type="other">Europe. W. Fact sheets on sustainable development goals: health targets. 2017.</mixed-citation></ref><ref id="pone.0227139.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Cassini</surname><given-names>A</given-names></name>, <name><surname>H&#x000f6;gberg</surname><given-names>LD</given-names></name>, <name><surname>Plachouras</surname><given-names>D</given-names></name>, <name><surname>Quattrocchi</surname><given-names>A</given-names></name>, <name><surname>Hoxha</surname><given-names>A</given-names></name>, <name><surname>Simonsen</surname><given-names>GS</given-names></name>, <etal>et al</etal>
<article-title>Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis</article-title>. <source>Lancet Infect Dis</source>. <year>2019</year>;<volume>19</volume>: <fpage>56</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(18)30605-4</pub-id>
<pub-id pub-id-type="pmid">30409683</pub-id></mixed-citation></ref><ref id="pone.0227139.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>O-Neill</surname><given-names>J.</given-names></name>
<source>Tackling drug-resistant infections globally: final report and recommendations</source>. <year>2016</year>.</mixed-citation></ref><ref id="pone.0227139.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Publishing</surname><given-names>O.</given-names></name>
<source>Stemming the Superbug Tide: Just A Few Dollars More</source>. <year>2018</year>.</mixed-citation></ref><ref id="pone.0227139.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Nikaido</surname><given-names>H.</given-names></name>
<article-title>Multidrug Resistance in Bacteria</article-title>. <source>Annu Rev Biochem</source>. <year>2009</year>; <pub-id pub-id-type="doi">10.1146/annurev.biochem.78.082907.145923</pub-id>
<pub-id pub-id-type="pmid">19231985</pub-id></mixed-citation></ref><ref id="pone.0227139.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Alekshun</surname><given-names>MN</given-names></name>, <name><surname>Levy</surname><given-names>SB</given-names></name>. <article-title>Molecular Mechanisms of Antibacterial Multidrug Resistance</article-title>. <source>Cell</source>. <year>2007</year>
<pub-id pub-id-type="doi">10.1016/j.cell.2007.03.004</pub-id>
<pub-id pub-id-type="pmid">17382878</pub-id></mixed-citation></ref><ref id="pone.0227139.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Blair</surname><given-names>JMA</given-names></name>, <name><surname>Webber</surname><given-names>MA</given-names></name>, <name><surname>Baylay</surname><given-names>AJ</given-names></name>, <name><surname>Ogbolu</surname><given-names>DO</given-names></name>, <name><surname>Piddock LJ</surname><given-names>V</given-names></name>. <article-title>Molecular mechanisms of antibiotic resistance</article-title>. <source>Nature Reviews Microbiology</source>. <year>2015</year>
<pub-id pub-id-type="doi">10.1038/nrmicro3380</pub-id>
<pub-id pub-id-type="pmid">25435309</pub-id></mixed-citation></ref><ref id="pone.0227139.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Higgins</surname><given-names>CF</given-names></name>. <article-title>Multiple molecular mechanisms for multidrug resistance transporters</article-title>. <source>Nature</source>. <year>2007</year>
<pub-id pub-id-type="doi">10.1038/nature05630</pub-id>
<pub-id pub-id-type="pmid">17429392</pub-id></mixed-citation></ref><ref id="pone.0227139.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Baym</surname><given-names>M</given-names></name>, <name><surname>Stone</surname><given-names>LK</given-names></name>, <name><surname>Kishony</surname><given-names>R</given-names></name>. <article-title>Multidrug evolutionary strategies to reverse antibiotic resistance</article-title>. <source>Science</source>. <year>2016</year>
<pub-id pub-id-type="doi">10.1126/science.aad3292</pub-id>
<pub-id pub-id-type="pmid">26722002</pub-id></mixed-citation></ref><ref id="pone.0227139.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Magiorakos</surname><given-names>AP</given-names></name>, <name><surname>Srinivasan</surname><given-names>A</given-names></name>, <name><surname>Carey</surname><given-names>RB</given-names></name>, <name><surname>Carmeli</surname><given-names>Y</given-names></name>, <name><surname>Falagas</surname><given-names>ME</given-names></name>, <name><surname>Giske</surname><given-names>CG</given-names></name>, <etal>et al</etal>
<article-title>Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance</article-title>. <source>Clin Microbiol Infect</source>. <year>2012</year>; <pub-id pub-id-type="doi">10.1111/j.1469-0691.2011.03570.x</pub-id>
<pub-id pub-id-type="pmid">21793988</pub-id></mixed-citation></ref><ref id="pone.0227139.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Liberati</surname><given-names>A</given-names></name>, <name><surname>Altman</surname><given-names>DG</given-names></name>, <name><surname>Tetzlaff</surname><given-names>J</given-names></name>, <name><surname>Mulrow</surname><given-names>C</given-names></name>, <name><surname>G&#x000f8;tzsche</surname><given-names>PC</given-names></name>, <name><surname>Ioannidis</surname><given-names>JPA</given-names></name>, <etal>et al</etal>
<article-title>The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration</article-title>. <source>Journal of clinical epidemiology</source>. <year>2009</year>
<pub-id pub-id-type="doi">10.1016/j.jclinepi.2009.06.006</pub-id>
<pub-id pub-id-type="pmid">19631507</pub-id></mixed-citation></ref><ref id="pone.0227139.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Mueller</surname><given-names>M</given-names></name>, <name><surname>D&#x02019;Addario</surname><given-names>M</given-names></name>, <name><surname>Egger</surname><given-names>M</given-names></name>, <name><surname>Cevallos</surname><given-names>M</given-names></name>, <name><surname>Dekkers</surname><given-names>O</given-names></name>, <name><surname>Mugglin</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Methods to systematically review and meta-analyse observational studies: a systematic scoping review of recommendations</article-title>. <source>BMC Med Res Methodol</source>. <year>2018</year>;<volume>18</volume>: <fpage>44</fpage>
<pub-id pub-id-type="doi">10.1186/s12874-018-0495-9</pub-id>
<pub-id pub-id-type="pmid">29783954</pub-id></mixed-citation></ref><ref id="pone.0227139.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Peikes</surname><given-names>DN</given-names></name>, <name><surname>Moreno</surname><given-names>L</given-names></name>, <name><surname>Orzol</surname><given-names>SM</given-names></name>. <article-title>Propensity Score Matching</article-title>. <source>Am Stat</source>. <year>2008</year>; <pub-id pub-id-type="doi">10.1198/000313008X332016</pub-id></mixed-citation></ref><ref id="pone.0227139.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Kurth</surname><given-names>T</given-names></name>, <name><surname>Walker</surname><given-names>AM</given-names></name>, <name><surname>Glynn</surname><given-names>RJ</given-names></name>, <name><surname>Chan</surname><given-names>KA</given-names></name>, <name><surname>Gaziano</surname><given-names>JM</given-names></name>, <name><surname>Berger</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect</article-title>. <source>Am J Epidemiol</source>. <year>2006</year>; <pub-id pub-id-type="doi">10.1093/aje/kwj047</pub-id>
<pub-id pub-id-type="pmid">16371515</pub-id></mixed-citation></ref><ref id="pone.0227139.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Stang</surname><given-names>A.</given-names></name>
<article-title>Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses</article-title>. <source>European Journal of Epidemiology</source>. <year>2010</year>
<pub-id pub-id-type="doi">10.1007/s10654-010-9491-z</pub-id>
<pub-id pub-id-type="pmid">20652370</pub-id></mixed-citation></ref><ref id="pone.0227139.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Hartling</surname><given-names>L</given-names></name>, <name><surname>Milne</surname><given-names>A</given-names></name>, <name><surname>Hamm</surname><given-names>MP</given-names></name>, <name><surname>Vandermeer</surname><given-names>B</given-names></name>, <name><surname>Ansari</surname><given-names>M</given-names></name>, <name><surname>Tsertsvadze</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Testing the Newcastle Ottawa Scale showed low reliability between individual reviewers</article-title>. <source>J Clin Epidemiol</source>. <year>2013</year>; <pub-id pub-id-type="doi">10.1016/j.jclinepi.2013.03.003</pub-id>
<pub-id pub-id-type="pmid">23683848</pub-id></mixed-citation></ref><ref id="pone.0227139.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Wells</surname><given-names>GA</given-names></name>
<etal>et al</etal>
<article-title>The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses</article-title>. <source>Evid based public Heal</source>. <year>2012</year>; <pub-id pub-id-type="doi">10.2307/632432</pub-id></mixed-citation></ref><ref id="pone.0227139.ref028"><label>28</label><mixed-citation publication-type="other">(2016), R Core Team R Foundation for Statistical Computing, Vienna A. R: A language and environment for statistical computing.</mixed-citation></ref><ref id="pone.0227139.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Schwarzer</surname><given-names>G.</given-names></name>
<article-title>meta: An R package for meta-analysis</article-title>. <source>R News</source>. <year>2007</year>;<volume>7</volume>: <fpage>40</fpage>&#x02013;<lpage>45</lpage>.</mixed-citation></ref><ref id="pone.0227139.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>IntHout</surname><given-names>J</given-names></name>, <name><surname>Ioannidis</surname><given-names>JPA</given-names></name>, <name><surname>Borm</surname><given-names>GF</given-names></name>. <article-title>The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method</article-title>. <source>BMC Med Res Methodol</source>. <year>2014</year>;<volume>14</volume>: <fpage>25</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2288-14-25</pub-id>
<pub-id pub-id-type="pmid">24548571</pub-id></mixed-citation></ref><ref id="pone.0227139.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Borenstein</surname><given-names>M</given-names></name>, <name><surname>Hedges</surname><given-names>L V</given-names></name>., <name><surname>Higgins</surname><given-names>JPT</given-names></name>, <name><surname>Rothstein</surname><given-names>HR</given-names></name>. <article-title>Notes on Subgroup Analyses and Meta-Regression</article-title>. <source>Introduction to Meta-Analysis</source>. <year>2009</year>
<pub-id pub-id-type="doi">10.1002/9780470743386.ch21</pub-id></mixed-citation></ref><ref id="pone.0227139.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Jackson</surname><given-names>D.</given-names></name>
<article-title>The power of the standard test for the presence of heterogeneity in meta-analysis</article-title>. <source>Stat Med</source>. John Wiley &#x00026; Sons, Ltd; <year>2006</year>;<volume>25</volume>: <fpage>2688</fpage>&#x02013;<lpage>2699</lpage>. <pub-id pub-id-type="doi">10.1002/sim.2481</pub-id>
<pub-id pub-id-type="pmid">16374903</pub-id></mixed-citation></ref><ref id="pone.0227139.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Hoaglin</surname><given-names>DC</given-names></name>. <article-title>Misunderstandings about Q and &#x02018;Cochran&#x02019;s Q test&#x0201d; in meta-analysis</article-title>.&#x02019; <source>Stat Med</source>. John Wiley &#x00026; Sons, Ltd; <year>2016</year>;<volume>35</volume>: <fpage>485</fpage>&#x02013;<lpage>495</lpage>. <pub-id pub-id-type="doi">10.1002/sim.6632</pub-id>
<pub-id pub-id-type="pmid">26303773</pub-id></mixed-citation></ref><ref id="pone.0227139.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>IntHout</surname><given-names>J</given-names></name>, <name><surname>Ioannidis</surname><given-names>JPA</given-names></name>, <name><surname>Rovers</surname><given-names>MM</given-names></name>, <name><surname>Goeman</surname><given-names>JJ</given-names></name>. <article-title>Plea for routinely presenting prediction intervals in meta-analysis</article-title>. <source>BMJ Open</source>. <year>2016</year>;<volume>6</volume>: <fpage>e010247</fpage>
<pub-id pub-id-type="doi">10.1136/bmjopen-2015-010247</pub-id>
<pub-id pub-id-type="pmid">27406637</pub-id></mixed-citation></ref><ref id="pone.0227139.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Egger</surname><given-names>M</given-names></name>, <name><surname>Smith</surname><given-names>GD</given-names></name>, <name><surname>Schneider</surname><given-names>M</given-names></name>, <name><surname>Minder</surname><given-names>C</given-names></name>. <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source>. <year>1997</year>;<volume>315</volume>: <fpage>629 LP</fpage>&#x02013; <lpage>634</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.315.7109.629</pub-id>
<pub-id pub-id-type="pmid">9310563</pub-id></mixed-citation></ref><ref id="pone.0227139.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Kopp</surname><given-names>BJ</given-names></name>, <name><surname>Nix</surname><given-names>DE</given-names></name>, <name><surname>Armstrong</surname><given-names>EP</given-names></name>. <article-title>Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections</article-title>. <source>Ann Pharmacother</source>. <year>2004</year>; <pub-id pub-id-type="doi">10.1345/aph.1E028</pub-id>
<pub-id pub-id-type="pmid">15266044</pub-id></mixed-citation></ref><ref id="pone.0227139.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Mauldin</surname><given-names>PD</given-names></name>, <name><surname>Salgado</surname><given-names>CD</given-names></name>, <name><surname>Hansen</surname><given-names>IS</given-names></name>, <name><surname>Durup</surname><given-names>DT</given-names></name>, <name><surname>Bosso</surname><given-names>JA</given-names></name>. <article-title>Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2010</year>; <pub-id pub-id-type="doi">10.1128/AAC.01041-09</pub-id>
<pub-id pub-id-type="pmid">19841152</pub-id></mixed-citation></ref><ref id="pone.0227139.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Carmeli</surname><given-names>Y</given-names></name>, <name><surname>Troillet</surname><given-names>N</given-names></name>, <name><surname>Karchmer</surname><given-names>AW</given-names></name>, <name><surname>Samore</surname><given-names>MH</given-names></name>. <article-title>Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa</article-title>. <source>Arch Intern Med</source>. <year>1999</year>; <pub-id pub-id-type="doi">10.1001/archinte.159.10.1127</pub-id>
<pub-id pub-id-type="pmid">10335691</pub-id></mixed-citation></ref><ref id="pone.0227139.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Resch</surname><given-names>A</given-names></name>, <name><surname>Wilke</surname><given-names>M</given-names></name>, <name><surname>Fink</surname><given-names>C</given-names></name>. <article-title>The cost of resistance: Incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals</article-title>. <source>Eur J Heal Econ</source>. <year>2009</year>; <pub-id pub-id-type="doi">10.1007/s10198-008-0132-3</pub-id>
<pub-id pub-id-type="pmid">19015905</pub-id></mixed-citation></ref><ref id="pone.0227139.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Neidell</surname><given-names>MJ</given-names></name>, <name><surname>Cohen</surname><given-names>B</given-names></name>, <name><surname>Furuya</surname><given-names>Y</given-names></name>, <name><surname>Hill</surname><given-names>J</given-names></name>, <name><surname>Jeon</surname><given-names>CY</given-names></name>, <name><surname>Glied</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Costs of healthcare-and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms</article-title>. <source>Clin Infect Dis</source>. <year>2012</year>; <pub-id pub-id-type="doi">10.1093/cid/cis552</pub-id>
<pub-id pub-id-type="pmid">22700828</pub-id></mixed-citation></ref><ref id="pone.0227139.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Micek</surname><given-names>ST</given-names></name>, <name><surname>Wunderink</surname><given-names>RG</given-names></name>, <name><surname>Kollef</surname><given-names>MH</given-names></name>, <name><surname>Chen</surname><given-names>C</given-names></name>, <name><surname>Rello</surname><given-names>J</given-names></name>, <name><surname>Chastre</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: Impact of multidrug resistance</article-title>. <source>Crit Care</source>. <year>2015</year>; <pub-id pub-id-type="doi">10.1186/s13054-015-0926-5</pub-id>
<pub-id pub-id-type="pmid">25944081</pub-id></mixed-citation></ref><ref id="pone.0227139.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Engemann</surname><given-names>JJ</given-names></name>, <name><surname>Carmeli</surname><given-names>Y</given-names></name>, <name><surname>Cosgrove</surname><given-names>SE</given-names></name>, <name><surname>Fowler</surname><given-names>VG</given-names></name>, <name><surname>Bronstein</surname><given-names>MZ</given-names></name>, <name><surname>Trivette</surname><given-names>SL</given-names></name>, <etal>et al</etal>
<article-title>Adverse Clinical and Economic Outcomes Attributable to Methicillin Resistance among Patients with <italic>Staphylococcus aureus</italic> Surgical Site Infection</article-title>. <source>Clin Infect Dis</source>. <year>2003</year>; <pub-id pub-id-type="doi">10.1086/367653</pub-id>
<pub-id pub-id-type="pmid">12594640</pub-id></mixed-citation></ref><ref id="pone.0227139.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Roberts</surname><given-names>RR</given-names></name>, <name><surname>Hota</surname><given-names>B</given-names></name>, <name><surname>Ahmad</surname><given-names>I</given-names></name>, <name><surname>Scott</surname><given-names>II RD</given-names></name>, <name><surname>Foster</surname><given-names>SD</given-names></name>, <name><surname>Abbasi</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Hospital and Societal Costs of Antimicrobial&#x02010;Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic Stewardship</article-title>. <source>Clin Infect Dis</source>. <year>2009</year>; <pub-id pub-id-type="doi">10.1086/605630</pub-id>
<pub-id pub-id-type="pmid">19739972</pub-id></mixed-citation></ref><ref id="pone.0227139.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Pelz</surname><given-names>RK</given-names></name>, <name><surname>Lipsett</surname><given-names>PA</given-names></name>, <name><surname>Swoboda</surname><given-names>SM</given-names></name>, <name><surname>Diener-West</surname><given-names>M</given-names></name>, <name><surname>Powe</surname><given-names>NR</given-names></name>, <name><surname>Brower</surname><given-names>RG</given-names></name>, <etal>et al</etal>
<article-title>Vancomycin-sensitive and vancomycin-resistant enterococcal infections in the ICU: Attributable costs and outcomes</article-title>. <source>Intensive Care Med</source>. <year>2002</year>; <pub-id pub-id-type="doi">10.1007/s00134-002-1276-8</pub-id>
<pub-id pub-id-type="pmid">12107672</pub-id></mixed-citation></ref><ref id="pone.0227139.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Riu</surname><given-names>M</given-names></name>, <name><surname>Chiarello</surname><given-names>P</given-names></name>, <name><surname>Terradas</surname><given-names>R</given-names></name>, <name><surname>Sala</surname><given-names>M</given-names></name>, <name><surname>Garcia-Alzorriz</surname><given-names>E</given-names></name>, <name><surname>Castells</surname><given-names>X</given-names></name>, <etal>et al</etal>
<article-title>Cost attributable to nosocomial bacteremia. Analysis according to microorganism and antimicrobial sensitivity in a university hospital in Barcelona</article-title>. <source>PLoS One</source>. <year>2016</year>; <pub-id pub-id-type="doi">10.1371/journal.pone.0153076</pub-id>
<pub-id pub-id-type="pmid">27055117</pub-id></mixed-citation></ref><ref id="pone.0227139.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Magira</surname><given-names>EE</given-names></name>, <name><surname>Islam</surname><given-names>S</given-names></name>, <name><surname>Niederman</surname><given-names>MS</given-names></name>. <article-title>Multi-drug resistant organism infections in a medical ICU: Association to clinical features and impact upon</article-title>. <source>Med Intensiva</source> (English Ed. Elsevier Espa&#x00026;ntilde;a, S.L.U. and SEMICYUC; <year>2018</year>;<volume>42</volume>: <fpage>225</fpage>&#x02013;<lpage>234</lpage>. <pub-id pub-id-type="doi">10.1016/j.medin.2017.07.006</pub-id>
<pub-id pub-id-type="pmid">29033075</pub-id></mixed-citation></ref><ref id="pone.0227139.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>Z</given-names></name>, <name><surname>Xu</surname><given-names>Z</given-names></name>, <name><surname>Wu</surname><given-names>H</given-names></name>, <name><surname>Chen</surname><given-names>L</given-names></name>, <name><surname>Gao</surname><given-names>S</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>. <article-title>The impact of carbapenem-resistant Pseudomonas aeruginosa on clinical and economic outcomes in a Chinese tertiary care hospital: A propensity score &#x02212; matched analysis</article-title>. <source>AJIC Am J Infect Control</source>. Elsevier Inc.; <year>2019</year>;<volume>47</volume>: <fpage>677</fpage>&#x02013;<lpage>682</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajic.2018.10.025</pub-id>
<pub-id pub-id-type="pmid">30554879</pub-id></mixed-citation></ref><ref id="pone.0227139.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Fern&#x000e1;ndez-Barat</surname><given-names>L</given-names></name>, <name><surname>Ferrer</surname><given-names>M</given-names></name>, <name><surname>De Rosa</surname><given-names>F</given-names></name>, <name><surname>Gabarr&#x000fa;s</surname><given-names>A</given-names></name>, <name><surname>Esperatti</surname><given-names>M</given-names></name>, <name><surname>Terraneo</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance</article-title>. <source>J Infect</source>. <year>2017</year>;<volume>74</volume>: <fpage>142</fpage>&#x02013;<lpage>152</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2016.11.008</pub-id>
<pub-id pub-id-type="pmid">27865895</pub-id></mixed-citation></ref><ref id="pone.0227139.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Tedja</surname><given-names>R</given-names></name>, <name><surname>Nowacki</surname><given-names>A</given-names></name>, <name><surname>Fraser</surname><given-names>T</given-names></name>, <name><surname>Fatica</surname><given-names>C</given-names></name>, <name><surname>Griffiths</surname><given-names>L</given-names></name>, <name><surname>Gordon</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>The impact of multidrug resistance on outcomes in ventilator-associated pneumonia</article-title>. <source>Am J Infect Control</source>. <year>2014</year>;<volume>42</volume>: <fpage>542</fpage>&#x02013;<lpage>545</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajic.2013.12.009</pub-id>
<pub-id pub-id-type="pmid">24630700</pub-id></mixed-citation></ref><ref id="pone.0227139.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Depuydt</surname><given-names>PO</given-names></name>, <name><surname>Vandijck</surname><given-names>DM</given-names></name>, <name><surname>Bekaert</surname><given-names>MA</given-names></name>, <name><surname>Decruyenaere</surname><given-names>JM</given-names></name>, <name><surname>Blot</surname><given-names>SI</given-names></name>, <name><surname>Vogelaers</surname><given-names>DP</given-names></name>, <etal>et al</etal>
<article-title>Determinants and impact of multidrug antibiotic resistance in pathogens causing ventilator-associated-pneumonia</article-title>. <source>Crit Care</source>. <year>2008</year>;<volume>12</volume>: <fpage>R142</fpage>
<pub-id pub-id-type="doi">10.1186/cc7119</pub-id>
<pub-id pub-id-type="pmid">19014695</pub-id></mixed-citation></ref><ref id="pone.0227139.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Martin-Loeches</surname><given-names>I</given-names></name>, <name><surname>Torres</surname><given-names>A</given-names></name>, <name><surname>Rinaudo</surname><given-names>M</given-names></name>, <name><surname>Terraneo</surname><given-names>S</given-names></name>, <name><surname>de Rosa</surname><given-names>F</given-names></name>, <name><surname>Ramirez</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organi</article-title>. <source>J Infect</source>. <year>2015</year>;<volume>70</volume>: <fpage>213</fpage>&#x02013;<lpage>222</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2014.10.004</pub-id>
<pub-id pub-id-type="pmid">25445887</pub-id></mixed-citation></ref><ref id="pone.0227139.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Puchter</surname><given-names>L</given-names></name>, <name><surname>Chaberny</surname><given-names>IF</given-names></name>, <name><surname>Schwab</surname><given-names>F</given-names></name>, <name><surname>Vonberg</surname><given-names>R-P</given-names></name>, <name><surname>Bange</surname><given-names>F-C</given-names></name>, <name><surname>Ebadi</surname><given-names>E</given-names></name>. <article-title>Economic burden of nosocomial infections caused by vancomycin-resistant enterococci</article-title>. <source>Antimicrob Resist Infect Control</source>. England; <year>2018</year>;<volume>7</volume>: <fpage>1</fpage>
<pub-id pub-id-type="doi">10.1186/s13756-017-0291-z</pub-id>
<pub-id pub-id-type="pmid">29312658</pub-id></mixed-citation></ref><ref id="pone.0227139.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Bonnet</surname><given-names>V</given-names></name>, <name><surname>Dupont</surname><given-names>H</given-names></name>, <name><surname>Glorion</surname><given-names>S</given-names></name>, <name><surname>Aupee</surname><given-names>M</given-names></name>, <name><surname>Kipnis</surname><given-names>E</given-names></name>, <name><surname>Gerard</surname><given-names>JL</given-names></name>, <etal>et al</etal>
<article-title>Influence of bacterial resistance on mortality in intensive care units: a registry study from 2000 to 2013 (IICU Study)</article-title>. <source>J Hosp Infect. England</source>; <year>2019</year>;<volume>102</volume>: <fpage>317</fpage>&#x02013;<lpage>324</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhin.2019.01.011</pub-id>
<pub-id pub-id-type="pmid">30659869</pub-id></mixed-citation></ref><ref id="pone.0227139.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Nelson</surname><given-names>RE</given-names></name>, <name><surname>Stevens</surname><given-names>VW</given-names></name>, <name><surname>Jones</surname><given-names>M</given-names></name>, <name><surname>Khader</surname><given-names>K</given-names></name>, <name><surname>Schweizer</surname><given-names>ML</given-names></name>, <name><surname>Perencevich</surname><given-names>EN</given-names></name>, <etal>et al</etal>
<article-title>Attributable Cost and Length of Stay Associated with Nosocomial Gram-Negative Bacterial Cultures</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2018</year>;<volume>62</volume>: <fpage>e00462</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00462-18</pub-id>
<pub-id pub-id-type="pmid">30150480</pub-id></mixed-citation></ref><ref id="pone.0227139.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Cowie</surname><given-names>SE</given-names></name>, <name><surname>Ma</surname><given-names>I</given-names></name>, <name><surname>Lee</surname><given-names>SK</given-names></name>, <name><surname>Smith</surname><given-names>RM</given-names></name>, <name><surname>Hsiang</surname><given-names>YN</given-names></name>. <article-title>Nosocomial MRSA infection in vascular surgery patients: impact on patient outcome</article-title>. <source>Vasc Endovascular Surg. United States</source>; <year>2005</year>;<volume>39</volume>: <fpage>327</fpage>&#x02013;<lpage>334</lpage>. <pub-id pub-id-type="doi">10.1177/153857440503900404</pub-id>
<pub-id pub-id-type="pmid">16079941</pub-id></mixed-citation></ref><ref id="pone.0227139.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Blot</surname><given-names>S</given-names></name>, <name><surname>Depuydt</surname><given-names>P</given-names></name>, <name><surname>Vandewoude</surname><given-names>K</given-names></name>, <name><surname>De Bacquer</surname><given-names>D</given-names></name>. <article-title>Measuring the impact of multidrug resistance in nosocomial infection</article-title>. <source>Curr Opin Infect Dis</source>. United States; <year>2007</year>;<volume>20</volume>: <fpage>391</fpage>&#x02013;<lpage>396</lpage>. <pub-id pub-id-type="doi">10.1097/QCO.0b013e32818be6f7</pub-id>
<pub-id pub-id-type="pmid">17609598</pub-id></mixed-citation></ref><ref id="pone.0227139.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Friedrich</surname><given-names>JO</given-names></name>, <name><surname>Adhikari</surname><given-names>NKJ</given-names></name>, <name><surname>Beyene</surname><given-names>J</given-names></name>. <article-title>The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: A simulation study</article-title>. <source>BMC Med Res Methodol</source>. <year>2008</year>;<volume>8</volume>: <fpage>32</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2288-8-32</pub-id>
<pub-id pub-id-type="pmid">18492289</pub-id></mixed-citation></ref></ref-list></back></article>